Ian Pitha, MD, PhD, argues that leveraging large-scale utilization data to identify the highest-impact medications could help the field get ahead of supply disruptions before they reach patients.
Ian Pitha, MD, MS
Advertisement
Articles by Ian Pitha, MD, MS
Pitha discusses how ophthalmic drug shortages — more frequent and longer-lasting than the national average — are threatening adherence to glaucoma therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
3
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
4
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
5